Astellas deal gives J&J new contender in arthritis JAK inhibitor race
This article was originally published in Scrip
Executive Summary
As part of its "multi-track" strategy of licensing out non-core pipeline molecules, Astellas has granted Janssen Biotech (Johnson & Johnson) global rights excluding Japan to an oral Janus kinase (JAK) inhibitor for immune-mediated inflammatory indications.